The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Abstract
Melanoma is the most aggressive skin cancer in humans that often expresses MHC class II (MHC II) molecules, which could make these tumors eliminable by the immune system. However, this MHC II expression has been associated with poor prognosis, and there is a lack of immune-mediated eradication. The lymphocyte activation gene-3 (LAG-3) is a natural ligand for MHC II that is substantially expressed on melanoma-infiltrating T cells including those endowed with potent immune-suppressive activity. Based on our previous data showing the signaling capacity of MHC II in melanoma cells, we hypothesized that LAG-3 could contribute to melanoma survival through its MHC II signaling capacity in melanoma cells. In this study, we demonstrate that both soluble LAG-3 and LAG-3–transfected cells can protect MHC II-positive melanoma cells, but not MHC II-negative cells, from FAS-mediated and drug-induced apoptosis. Interaction of LAG-3 with MHC II expressed on melanoma cells upregulates both MAPK/Erk and PI3K/Akt pathways, albeit with different kinetics. Inhibition studies using specific inhibitors of both pathways provided evidence of their involvement in the LAG-3–induced protection from apoptosis. Altogether, our data suggest that the LAG-3–MHC II interaction could be viewed as a bidirectional immune escape pathway in melanoma, with direct consequences shared by both melanoma and immune cells. In the future, compounds that efficiently hinder LAG-3–MHC II interaction might be used as an adjuvant to current therapy for MHC II-positive melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
Self-citationMatsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Apoptosis and cancer: the genesis of a research field
Cotter, T. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2663 · Cited by 758
Viguier, M., Lemaître, F., Verola, O., Cho, M.-S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., & Ferradini, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1444 · Cited by 686
Self-citationGrosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 547
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., & Drake, C. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5164 · Cited by 427
Baixeras, E., Huard, B., Miossec, C., Jitsukawa, S., Martin, M., Hercend, T., Auffray, C., Triebel, F., & Piatier-Tonneau, D. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.2.327 · Cited by 397
Self-citationHuard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250949 · Cited by 391
Self-citationCamisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903879 · Cited by 350
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)
Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 332
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley, K. S. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10978 · Cited by 325
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 319
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein
Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., El-Tayar, N., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308
Self-citationApoptosis and melanoma: molecular mechanisms
Hussein, M. R., Haemel, A. K., & Wood, G. S. (2003) · The Journal of Pathology · doi:10.1002/path.1300 · Cited by 272
Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006) · Blood · doi:10.1182/blood-2006-04-015164 · Cited by 255 · cited 1×
“ulatory function of tumor-infiltrated T cells in cancer, such as in Hodgkin’s lymphomas (24) and in prostate cancer (25).”
BackgroundCD3/TCR complex‐associated lymphocyte activation gene‐3 molecules inhibit CD3/TCR signaling
Hannier, S., Tournier, M., Bismuth, G., & Triebel, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4058 · Cited by 248
Self-citationHuard, B., Tournier, M., Hercend, T., Triebel, F., & Faure, F. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241246 · Cited by 241
Self-citationDeath receptors and melanoma resistance to apoptosis
Ivanov, V. N., Bhoumik, A., & Ronai, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206456 · Cited by 211
Maçon‐Lemaître, L., & Triebel, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02145.x · Cited by 192
Self-citationInterplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis
Lee, E.-R., Kim, J.-Y., Kang, Y.-J., Ahn, J.-Y., Kim, J.-H., Kim, B.-W., Choi, H.-Y., Jeong, M.-Y., & Cho, S.-G. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.06.006 · Cited by 190
CD95, BIM and T cell homeostasis
Bouillet, P., & O'Reilly, L. A. (2009) · Nature Reviews Immunology · doi:10.1038/nri2570 · Cited by 190
Cotargeting survival signaling pathways in cancer
Grant, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36898 · Cited by 164
Wang, H. Y., Peng, G., Guo, Z., Shevach, E. M., & Wang, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2661 · Cited by 157
Chekenya, M., Krakstad, C., Svendsen, A., Netland, I. A., Staalesen, V., Tysnes, B. B., Selheim, F., Wang, J., Sakariassen, P. Ø., Sandal, T., et al. (2008) · Oncogene · doi:10.1038/onc.2008.157 · Cited by 152
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
Triebel, F. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.10.001 · Cited by 150
Self-citationAndreae, S., Buisson, S., & Triebel, F. (2003) · Blood · doi:10.1182/blood-2003-01-0273 · Cited by 150
Self-citationMHC class II signaling in antigen-presenting cells
Al‐Daccak, R., Mooney, N., & Charron, D. J. (2003) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.11.006 · Cited by 146
Self-citationPI-3-K and AKT: Onto the mitochondria☆
Stiles, B. L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.017 · Cited by 146
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
Smalley, K. S. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.177 · Cited by 144
Nagy, Z. A., Hubner, B., Löhning, C., Rauchenberger, R., Reiffert, S. U., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E. M., Zahradnik, A., et al. (2002) · Nature Medicine · doi:10.1038/nm736 · Cited by 141
Cotargeting survival signaling pathways in cancer
Grant, S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36898e1 · Cited by 141
Avice, M.-N., Sarfati, M., Triebel, F., Delespesse, G., & Demeure, C. E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2748 · Cited by 130
Self-citationDarlington, P. J., Baroja, M. L., Chau, T. A., Siu, E., Ling, V., Carreno, B. M., & Madrenas, J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011868 · Cited by 127
Avice, M.-N., Sarfati, M., Triebel, F., et al. (1999) · PubMed · Cited by 114
Self-citationMHC antigens in human melanomas.
Dj, R., Mattijssen, V., Broecker, E.-B., & Ferrone, S. (1991) · PubMed · Cited by 111
Demeure, C. E., Wolfers, J., Martin‐Garcia, N., Gaulard, P., & Triebel, F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00184-8 · Cited by 104
Self-citationLAG-3 does not define a specific mode of natural killing in human
Huard, B., Tournier, M., & Triebel, F. (1998) · Immunology Letters · doi:10.1016/s0165-2478(97)00170-3 · Cited by 95
Self-citationCD95L/FasL and TRAIL in Tumour Surveillance and Cancer Therapy
Wajant, H. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_7 · Cited by 81
Mirmohammadsadegh, A., Mota, R., Gustrau, A., Hassan, M., Nambiar, S., Marini, A., Bojar, H., Tannapfel, A., & Hengge, U. R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700870 · Cited by 80
Yang, S., & Haluska, F. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4599 · Cited by 77
Chetoui, N., Sylla, K., Gagnon-Houde, J.-V., Alcaïde‐Loridan, C., Charron, D. J., Al‐Daccak, R., & Aoudjit, F. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0080 · Cited by 75
Self-citationDeffrennes, V., Vedrenne, J., Stolzenberg, M., Piskurich, J. F., Barbieri, G., Ting, J. P. ‐., Charron, D. J., & Alcaïde‐Loridan, C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.98 · Cited by 72
Self-citationSoluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity
Casati, C., Camisaschi, C., Rini, F., Arienti, F., Rivoltini, L., Triebel, F., Parmiani, G., & Castelli, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2728 · Cited by 72
Self-citationHannier, S., & Triebel, F. (1999) · International Immunology · doi:10.1093/intimm/11.11.1745 · Cited by 72
Self-citationAriza, M. E., Broome-Powell, M., Lahti, J. M., Kidd, V. J., & Nelson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28505 · Cited by 67
Rømer, M. U., Larsen, L., Offenberg, H., Brünner, N., & Lademann, U. A. (2008) · Neoplasia · doi:10.1593/neo.08486 · Cited by 58
Michel, L., Dupuy, A., Jean‐Louis, F., Sors, A., Poupon, J., Viguier, M. A., Musette, P., Dubertret, L., Degos, L., Dombret, H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12479.x · Cited by 51
Self-citationByun, H., Jung, W., Lee, D., Kim, S., Kim, S. J., Park, C., Chung, H. Y., & Chun, T. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.002 · Cited by 42
Byrne, S. N., & Halliday, G. M. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0380-0 · Cited by 33
Martins, I., Sylla, K., Deshayes, F., Lauriol, J., Ghislin, S., Dieu‐Nosjean, M., Viguier, M. A., VEROLA, O., Charron, D. J., Alcaïde‐Loridan, C., et al. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e32832e0bc3 · Cited by 24
Self-citation
Cited by
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
Metadata
- Authors
- Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., Triebel, F., Charron, D., Aoudjit, F., Al-Daccak, R., & Michel, L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-01
- Volume
- 186
- Issue
- 9
- Pages
- 5173-5183
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2100553040
- Cited by
- 252
- References
- 52
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.